

RealRate

PHARMACEUTICAL 2017

Jazz Pharmaceuticals plc Rank 4 of 292









PHARMACEUTICAL 2017





Jazz Pharmaceuticals plc Rank 4 of 292

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 4.9% points.

The company's Economic Capital Ratio, given in the ranking table, is 324%, being 321% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	748,069
Cost of Goods Sold	0
Intangible Assets	3,905,811
Liabilities, Current	257,406
Liabilities, Non-Current	0
Other Assets	38,857
Other Compr. Net Income	-49,861
Other Expenses	342,616
Other Liabilities	0
Other Net Income	-59,587
Other Revenues	1,487,973
Property and Equipment	107,490
Research and Development	186,047
Selling, General and Administrative Expense	502,892

Output Variable	Value in 1000 USD
Assets	4,800,227
Liabilities	257,406
Expenses	1,031,555
Revenues	1,487,973
Stockholders Equity	4,542,821
Net Income	396,831
Comprehensive Net Income	371,900
Economic Capital Ratio	324%

